What did @peters_peptides actually say?
The creator made several interconnected claims: that peptides are not a single category, that their side effects are mild and manageable, that they differ fundamentally from anabolic steroids, and that "clinical trials have shown no adverse effects" when peptides are used flexibly. They also predicted peptides will become as routine as multivitamins within a decade.
Credit where it is due: the point about lumping all peptides together is genuinely valid. Calling GLP-1 receptor agonists and MK-677 "the same thing" is like calling aspirin and chemotherapy both "drugs." That framing deserves acknowledgment. But some of the follow-up claims get sloppy in ways that matter.
Does the science back this up?
Partially, yes. But the claim that "clinical trials have shown no adverse effects" is simply not accurate, and that line should not go unchallenged.
GLP-1 agonists like semaglutide, which the creator references under the GLP-1 umbrella, have documented adverse event profiles including pancreatitis risk, thyroid C-cell tumors in rodent models, and gastroparesis. Wilding et al. (2021, New England Journal of Medicine) documented nausea and gastrointestinal events in over 40% of trial participants. BPC-157, often cited as benign, has limited human trial data, and most evidence remains preclinical. Ng et al. (2023, Frontiers in Pharmacology) reviewed BPC-157 animal studies and noted promising healing signals but explicitly flagged the absence of strong human safety data. MK-677, an oral ghrelin mimetic, raises IGF-1 levels and has been associated with water retention, insulin resistance, and in older adults, increased rates of congestive heart failure in at least one trial (Nass et al., 2008, Journal of Clinical Endocrinology and Metabolism). Saying these compounds share a profile of "minimal" side effects flattens real distinctions.
What did they get wrong (or right)?
They got the category problem right. They got the steroid comparison mostly right. They got the "clinical trials show no adverse effects" claim wrong, and that is the most consequential error in the video.
The steroid analogy is actually useful. Anabolic androgenic steroids suppress the hypothalamic-pituitary-gonadal axis, and recovery post-cycle is not guaranteed. Most therapeutic peptides do not work this way. That distinction is real. However, "hop on and hop off right away if something feels off" undersells the fact that some peptides, particularly those that elevate growth hormone or IGF-1, can have effects that outlast use. GHK-Cu topically is relatively low-risk. MK-677 affecting insulin sensitivity is not something that simply resets at discontinuation for all users.
The multivitamin comparison is also worth flagging. Vitamins are not injected, not regulated as biologics, and do not modulate growth hormone axes. That comparison minimizes regulatory and safety distinctions that exist for real reasons.
What should you actually know?
The honest answer is that peptide safety profiles vary enormously by compound, route of administration, dose, and individual health status. That is not fearmongering. It is the actual state of the evidence.
Most peptides discussed in fitness and longevity communities lack Phase 3 human trial data. BPC-157 has never completed an approved human clinical trial. TB-500 fragments are similarly under-studied in humans. GLP-1 agonists are the exception, with substantial trial data, and that data shows real side effects, not just constipation. Anyone evaluating a peptide protocol deserves to know which category they are dealing with: a compound with human trial data, or one where the safety case is built almost entirely on rodent studies and anecdote. The creator's video does not make that distinction, and for a 184,000-view video, that gap matters. Consulting a licensed clinician who can review your individual health history is not optional for these compounds. It is the baseline.